Glycoproteomic Analysis of Mouse Mammary Cell Lines During EMT Induced by TGF-β
Author Information
Author(s): Jennifer J. Hill, Tammy-Lynn Tremblay, Christiane Cantin, Maureen O'Connor-McCourt, John F. Kelly, Anne E.G. Lenferink
Primary Institution: Institute for Biological Sciences, National Research Council Canada
Hypothesis
To identify EMT-related breast cancer therapeutic targets and biomarkers by analyzing protein changes during TGF-β induced EMT in mouse mammary cell lines.
Conclusion
The study found that TGF-β induces different protein expression changes in two mouse mammary cell lines, suggesting distinct mechanisms of EMT.
Supporting Evidence
- TGF-β induces similar EMT phenotypes in both cell lines but with minimal overlap in proteomic results.
- Five proteins were identified as differentially expressed in BRI-JM01 cells after TGF-β treatment.
- Proteomic studies suggest that glycoproteins may undergo more changes in expression than soluble proteins.
Takeaway
Researchers looked at how two types of mouse breast cells change when treated with a substance that can help cancer grow, finding that they respond differently.
Methodology
Proteomic approaches including two-dimensional electrophoresis and lectin affinity followed by mass spectrometry were used to analyze protein changes.
Potential Biases
Potential bias due to the focus on glycoproteins may overlook other important proteins involved in EMT.
Limitations
The study used conservative cut-off values which may have led to missing some differentially expressed proteins.
Participant Demographics
Mouse mammary epithelial cell lines, specifically BRI-JM01 and NMuMG.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website